Physician profile
Chase Vargo
NPI 1043066483
$437.12
in general payments reported to CMS, 2019-2025
8 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $194 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $437.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $140.24 | 2024-2025 | |
| Amgen INC. | $126.46 | 2024 | Repatha |
| Novo Nordisk INC | $64.42 | 2024-2025 | Wegovy |
| Viatris Specialty LLC | $29.22 | 2025 | Yupelri |
| Exact Sciences Corporation | $20.63 | 2025 | The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $19.66 | 2025 | Capvaxive, Gardasil 9 |
| Collegium Pharmaceutical, INC. | $19.30 | 2025 | Jornay Pm |
| Pfizer INC. | $17.19 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chase Vargo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.